Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Plans $45 Mil. On Altace DTC Campaign; DREAMs Of Diabetes Indication

Executive Summary

King and Wyeth-Ayerst expect to spend approximately one-half of the $90 mil. set aside for Altace promotion on direct-to-consumer advertising for the ACE inhibitor.

You may also be interested in...



King Altace Scripts Shift To 10 Mg; Dosage From HOPE Trial Helps Fuel Growth

Prescriptions for King's ACE inhibitor Altace (ramipril) are shifting to the 10 mg strength, the same dose used in the Heart Outcomes Prevention Evaluation study, CEO Jefferson Gregory said

King Altace Scripts Shift To 10 Mg; Dosage From HOPE Trial Helps Fuel Growth

Prescriptions for King's ACE inhibitor Altace (ramipril) are shifting to the 10 mg strength, the same dose used in the Heart Outcomes Prevention Evaluation study, CEO Jefferson Gregory said

Novavax To Increase Sales Force To 100; Will Co-Promote Estrasorb With King

Novavax plans to ramp up its sales force from 65 reps to 100 reps in preparation for the launch of its estrogen replacement cream Estrasorb.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel